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EXTENT OF SKELETAL INVOLVEMENT DID NOT PREDICT FOR OUTCOME
AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR PATIENTS WITH
MULTIPLE MYELOMA
Seba, A., Farhat, M., Tuncer, H., Nathan, S., Gregory, S.A., Fung, H.C.
Rush University Medical Center, Chicago, IL
Background: Autologous stem cell transplant lengthens survival
in patients with multiple myeloma, but has mortality from infections
and high costs. Determination of prognostic factors predicting pro-
longed survival prior to transplant may help determine which pa-
tients may be better candidates for autologous SCT. Here, we
hypothesized that extensive skeletal involvement prior to transplant
predicted for adverse transplant outcome.
Methods: Patients undergoing autologous stem cell transplants
from 1999 to 2003 at Rush University Medical Center were reviewed
to determine if having fewer lytic lesions prior to stem cell transplant
there would lead to longer disease free survival post-transplant. Pa-
tients with less than 3 lytic lesions were compared to those with more
than three lytic lesions regardless of subtype of myeloma or time to
transplant. 83 patients had autoSCT at RUMC during the time
frame, 12 patients did not have documented skeletal surveys and
one patient underwent alloSCT, so they were not included in the
analysis. Of the remaining 70, 44 patients had numerous lesions
while 26 had 0–2 lesions. The mean age at SCT for both groups
was 55.6 years. The various subtypes of myeloma for the group of
44 patients with numerous lesion is 25 with IgG, 6 with IgA, 1
with IgD, 5 with light chain, and 7 that were not specified, and for
the group of 26 patients with 0–2 lesions, 19 were IgG, 2 IgA, 4
not specified and 1 with POEMS. The average time to transplant
from diagnosis was 624 days with a range of 117–2294 for the group
with 0–2 lesions, and 511 days with a range of 93–7321 days for the
group with numerous lesions.
Results: 28/44 patients with numerous lesions had documented
disease progression with a median of 27 months from transplant,
with ranges of 4–74 months, while 19/26 patients with fewer lesions
progressed with median of 35 months and range of 12–75 months.
Prior to August 2008, 15/44 patients in the group with numerous le-
sions died, while 19/26 patients in the group with fewer lesions died.
Analysis with Kaplan Meyer survival curves showed no difference in
disease free survival and death between the two groups, with p-values
of 0.34 and 0.53 respectively. The estimated 5-year survival was 60%
versus 50% for pts with 0–2 lesions versus numerous lesions respec-
tively.
Conclusions:We conclude that extent of skeletal involvement de-
fined by number of lytic lesions does not predict for transplant out-
come in patients with multiple myeloma.GRAFT PROCESSING
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DEVELOPMENT OF A SEGMENT-BASED ALDEHYDE DEHYDROGENASE
ASSAY TO DETERMINE UMBILICAL CORD BLOOD UNIT (CBU) POTENCY
Shoulars, K.W.1, Gentry, T.2, Tracy, E.T.1, Page, K.1, Sun, J.1,
Winstead, L.2, Balber, A.E.2, Kurtzberg, J.1 1Duke University Medical
Center, Durham, NC; 2Aldagen, Durham, NC
Background: Banked, unrelated CBU provides access to trans-
plantation for patients lacking matched donors. However, after CB
transplantation (UCBT), up to 20% of patients experience primary
graft failure, suggesting that rapid assays to assess CB potency are
needed. Preliminary clinical studies demonstrated that post-thaw
colony forming units (CFU) predict neutrophil and platelet engraft-
ment as well as overall survival but, time (14 days) and variability
limit their usefulness as a potency assay. CFUs in fresh cord blood
are highly correlated with the number of cord blood cells expressing
aldehyde dehydrogenase (ALDHbr), an enzyme enriched in hemato-
poietic progenitor and stem cells. Therefore, we developed an assay
for ALDHbr cells in segments attached to CBUs to measure potency
for UCBT.
Methods: Fresh CBUs, donated to the Carolinas Cord Blood
Bank at Duke, were selected based on ALDHbr content (high1.0%,
medium0.4%, low0.1%) and divided into segments (100 ul) for
cryopreservation and post-thaw testing. Thawed segments werewashed to remove the DMSO with 5% dextran/albumin (DA) or
1% human serum albumin/phosphate buffered saline (HSA/PBS).
The segments were assayed for CFU [Methocult], ALDHbr [Alde-
fluor], viability, expression of CD34, CD45 and Glycophorin A
[flow cytometry] and total nucleated cell (TNC) count [Sysmex],
and total number of each cell population in the segment pre-cryo
and post-thaw was calculated.
Results:ALDHbr cells (85% CD34/45 positive) were reproduc-
ibly assayed by flow cytometry in fresh and frozen segments in less
than a day regardless of ALDHbr percentage. DA and HSA/PBS
washes reliably removed DMSO with little loss in the number of
CFU or ALDHbr cells, although TNC count was reduced. Ammo-
nium chloride lysis of red blood cells post-thaw reduced CFU and
ALDHbr cells, so an alternate procedure based on exclusion gating
of GLY A1 cells was adopted. Studies on segments derived from
the same cord showed that the number of ALDHbr cells could be re-
liably measured and that pre-cryo and post-thaw changes in CFU
and ALDHbr cells strongly correlated.
Conclusions: ALDHbr cell content of thawed CBU segments can
be measured rapidly and reliably by flow cytometry. Post-thaw
ALDHbr correlates with CFUs. Since post-thaw CFU values predict
engraftment, we propose further studies of a rapid, post-thaw assay
of ALDHbr content that could serve as a predictor of CBU potency
for neutrophil and platelet engraftment and overall survival after
UCBT.112
SIGNIFICANT EX-VIVO EXPANSION OF CORD BLOOD (CB) NATURAL
KILLER (NK) CELLS AND CONCOMITANT DECREASE IN CB T-CELLS BY
GENETICALLY REENGINEERED K562 CELLS (K562-MBIL15-41BBL)
Hochberg, J.1, Mar, B.1, Ayello, J.1, Day, N.1, van de Ven, C.1, Ricci, A.1,
Gurnani, L.1, Cairo, E.1, Campana, D.2, Cairo,M.S.1,3,4 1Morgan Stan-
ley Children’s Hospital NewYork Presbyterian, ColumbiaUniversity, New
York, NY; 2St. Jude Children’s Research Hospital, Memphis, TN; 3Mor-
gan Stanley Children’s Hospital New York Presbyterian, Columbia Uni-
versity, New York, NY; 4Morgan Stanley Children’s Hospital New York
Presbyterian, Columbia University, New York, NY
The limitations of the use of NK cells in adoptive tumor immuno-
therapy include lack of tumor recognition by NK cells and limited
numbers of functionally active NK cells (Shereck/Cairo et al, Pediatr
Blood Cancer, 2007). To circumvent these limitations, methods to
expand and activate peripheral blood NK cells have been developed
(Imai et al, Blood, 2005). We previously reported the successful ex-
pansion and functional activation of cord blood NK cells by ex-vivo
cellular engineering with a cocktail of antibody and cytokines
(Ayello/Cairo et al, BBMT, 2006). In this study we sought to develop
an improved CB NK cell expansion system for use in adoptive cellu-
lar immunotherapy strategies. Freshly isolated CB mononuclear
cells (CBMC) were cultured with modified K562 cells expressing
membrane bound IL15 and 4-1BB ligand (K562-mbIL15-41BBL;
Imai et al, Blood, 2005). After irradiation with 100Gy,
K562-mbIL15-41BBL cells were incubated in a 1:1 ratio with
CBMC1 10 IU/mL rhIL-2 for 7–14 days. CD3 and CD56 expres-
sion was determined by flow cytometry at Days 0, 7 and 14. On Day
0, CBMC included a population of CD561/CD3- NK cells of 3.9%
6 1.3%. After 7 days of culture with K562-mbIL15-41BBL cells the
percentage of NK cells increased to 71.7%6 3.9%, as compared to
9.7%6 2.4% in cultures with media alone and 42.6%6 5.9% in cul-
tures with wild-type K562 cells (p\0.01). Concomitantly, there was
a significant decrease in CB T-Cells vs culture with wild-type K562
or media alone (15.1 6 1.7% vs 35.7 6 2.4% vs 51 6 7.1%, respec-
tively) (p\0.001). Overall, this represented a 35-fold or 3374% 6
385% increase of the input NK cell number. This was significantly
increased compared to culture with wild-type K562 (1771% 6
300%, p\0.05). On Day 14, there remained a significant increase
in NK cell populations between CBMC incubated with modified
K562 cells compared to wild-type K562 cells and media alone
(62.0% 6 2.1% vs 27.9% 6 2.4% vs 5.5% 6 0.4%, p\0.001). A
standard cryopreserved UCB unit (25 mL) contains approximately
750  106 MNCs. By using the smaller 5mL aliquot (20%) of
a two-aliquot bag (150  106 MNCs x 3.9%5 5.8  106 NK cells),
this expansion method would hypothetically yield approximately 200
 106 CB NK cells after 7 days of culture. In summary, we have
